Good morning. My name is Antoine. I'm the CEO of Ferrante's Pharma. And welcome to the first half remote report webinar for this pharma. So first, the necessary forward-looking statements. And let's go then into the company update followed by the first half report.
Highlights. Here at Ferrante's Pharma, we are a clinical-stage public company and we develop disease-modifying therapies for Parkinson's disease and other neurodegenerative diseases. And our lead asset is HER-096. That is a peptide that mimics a CNF protein. And CNF protein has been earlier shown to break the cycle of Parkinson's disease pathogenesis. And last year we completed the Phase 1 clinical study with HER-096, demonstrating brain penetration and a good safety profile after subcutaneous administration.
What is very specific for HER-096 is that we actually have signs of efficacy already in clinical settings, with the mother molecule, as we call it, the CNF, in the Phase 1 clinical study with fairly advanced Parkinson's patients. And this is truly unique. And combine this with the strong preclinical data of HER-096, demonstrating the mechanism of action, the activity in Parkinson's disease pathogenesis, and the ability to affect the symptoms in Parkinson's models is a great combination to work with and continue with the clinical development. I want to also highlight the team, both the operational team at the company. But our very experienced board and the advisory board, consisting of senior industry experts in the clinical development of therapeutics up to the market.
So we believe that this is a great combination with the great biology that we are working with. So why is innovation needed for Parkinson's disease? The current therapies only treat symptoms. They don't affect disease progression. Currently, there is no cure for Parkinson's disease. And even with the current symptomatic treatment, it is not always efficacious.
There are also significant side effects. So, it's clear that there is a high unmet clinical need and all the Parkinson's patients are really eagerly waiting for new types of drugs that can really slow down or even stop the progression of the disease, hopefully at the early stage of the disease, so that the patients can keep up with their normal life, which is currently not possible longer term. If you look at the market currently, the market size for Parkinson's disease therapeutics is approximately 5 billion USD, and it's expected to grow up to 10 billion by 2030. And this growth will be driven by the development of disease-modifying treatments, such as HER-096, and, based on our market research, we can have a big share of that market.
That global market will be addressed once, and if HER-096 reaches the market. And these figures only show the potential in Parkinson's disease as we know. Also, the same kind of biology could be used also in other neurodegenerative diseases later on. About the mechanism of action. So Parkinson's disease is caused by the degeneration of neurons in a certain area in the midbrain. And a hallmark of that degeneration is one pathway called unfolded protein response pathway that is chronically activated in Parkinson's patients, resulting in neuron degeneration and eventually the death of the neurons. Uh, accumulation of toxic alpha-synuclein aggregates and neuroinflammation. And what we have been able to show in preclinical settings is that we can break this cycle and reprogram the neurons to act normally so that they can keep up with the normal functions and production of the dopamine that controls motor functions in humans. So the key advantages of HER-096 are its neuro-restorative properties. Uh, we have significant evidence of that. We can administer HER-096 subcutaneously, which is quite unique, as many of the disease-modifying drug candidates have to be delivered intracranially. And we have very good safety data in clinical settings already. So what is the status of the data currently? So could we have the video here? Yes. So what we have shown in preclinical settings is that we can affect the symptoms. In this video, the first mouse is a normal mouse walking over a bar in a walking test for motor coordination. The second mouse has induced Parkinson's-like pathology. And it's really struggling to coordinate its movements. Uh, and the third mouse, like the second one with pathology but treated subcutaneously with HER-096. And as you can see, we have been able to reduce the motor symptoms. We know that the improvement is due to the increased amount of dopamine in the brain, which is a result of stabilizing the unfolded protein response pathway, the target mechanism. And we have a truly robust data set demonstrating the whole chain from the mechanistic intervention in that pathway to the effect on the motor symptoms. And this is, of course, very encouraging. And this is what we aim to translate into patient studies going forward. Last year, we completed a Phase 1a clinical trial in healthy individuals. And there on the left-hand side, you see the results of the brain penetration. In that study, we demonstrated that after a single subcutaneous administration of HER-096, we were able to achieve a concentration of HER-096 in cerebrospinal fluid. So in the CNS, between 50 and 100 nanograms per mL. Uh, which is well within the therapeutic range of HER-096, as shown in preclinical settings. And on the right-hand side, there is a graph about the pharmacokinetics and the profile. The pharmacokinetic profile in plasma is very good and as expected. This data provides us a great starting point for a Phase 1b clinical trial that we expect to start later this year. The Phase 1b clinical trial is a necessary step from Phase 1a to the Phase 2 clinical trials. And in Phase 1b, the objectives are to first of all demonstrate the safety and tolerability of repeated dosing in Parkinson's patients, but also to study the pharmacokinetics and biological responses to HER-096 administration using biomarker data.
In the study, we have up to 16 healthy individuals to complete the pharmacokinetic study. And then we have 20 to 24 Parkinson's patients who will be administered HER-096 subcutaneously twice a week for four weeks. And then we are, of course, closely monitoring the effects of HER-096 in these patients. And we are really enthusiastic about this study. It's great that we are now able to soon start the first study of HER-096 in actual patients. Um, so that's a great milestone for the company and an important preparation towards the Phase 2 clinical trials. And in Phase 2 studies. The objective is to demonstrate the safety. So, the effect of HER-096 on Parkinson's disease. And let's go now. Report and the results. So, first of all, about the business highlights from the first half. We submitted a clinical trial application for the Phase 1b Clinical Trial in May. And then that study will take place in Finland. And we expect soon to get the approval and start the clinical study by the end of the year. We also received a milestone payment of $750,000 from the EIC Accelerator grant that we originally obtained on April 23rd. Very happy about the events of the reporting period. On July 1st, we announced that we secured research funding from the European Innovation Council. Fox Foundation and Parkinson's UK through the Parkinson's Virtual Biotech. They will finance our Phase 1b Clinical Trial and advanced biomarker efforts. The board has also decided on a new options rights program for key personnel. Let's spend a minute discussing the research funding that we obtained from the Michael J. Fox Foundation and Parkinson's UK. These two charities are the leading charities for Parkinson's disease research globally, especially the Michael J. Fox Foundation. Fox's stamp on our program delivers quite a bit of value for us, preparing for the next clinical studies and also from a partnering point of view, as this strategy has made a scientific evaluation of our assets. And they believe that HER-096 is among the best candidates that could address the unmet clinical need of Parkinson's disease. And here I also want to highlight that, since April 2023, we have been able to secure 6.1 million of non-dilutive research funding from these charities and from the European Union through their European Innovation Council accelerator grant. And both of these finances have involved the scientific evaluation of our asset. And we are really happy about this. Combine this with the commitment of, uh, the European Innovation Council (EIC) fund, including direct equity investments of up to €15 million, from which we raised €1.5 million earlier. This is a great achievement for guarantees going forward. So maybe you will take us through the financials. Yes.